Table 2 Univariate and multivariate analyses of PFS and OS using Cox regression models in patients with first-line treatments.

From: Prognostic significance of circulating tumor DNA alterations in advanced renal cell carcinoma from SCRUM-Japan MONSTAR-SCREEN: a nationwide genomic profiling project

 

PFS

OS

Variable

Univariate analysis

 

Multivariate analysis

Univariate analysis

 

Multivariate analysis

 
 

HR

p value

HR

p value

HR

p value

HR

p value

Sex

Male

Reference

       

Female

1.027 (0.435–2.381)

0.749

1.131 (0.577-2.217)

0.720

1.945 (0.850–4.453)

0.128

1.622 (0.668–3.941)

0.284

Age, years

<75

Reference

       

≥75

1.576 (0.149–2.683)

0.596

1.534 (0.142–2.961)

0.577

1.778 (0.605–5.228)

0.296

1.481 (0.538–4.948)

0.385

Number of metastatic sites

Single

Reference

       

Multiple

1.151 (0.587–2.254)

0.683

1.006 (0.451–2.244)

0.988

1.095 (0.637–1.883)

0.742

1.259 (0.552–2.878)

0.417

IMDC risk

Favorable

Reference

       

Intermediate/Poor

1.784 (0.739–4.364)

0.204

2.378 (0.774–8.395)

0.468

2.165 (0.922–5.084)

0.076

1.389 (0.893–3.911)

0.114

CRP

<1.0

Reference

       

≥1.0

1.773 (0.812–4.408)

0.118

2.235 (0.803–3.215)

0.123

1.384 (0.775–2.471)

0.272

1.020 (0.508–2.034)

0.860

Pre-TF

<1.2%

Reference

       

≥1.2%

2.074 (1.174–3.664)

0.014

1.699 (1.818–3.680)

0.043

2.186 (0.976–4.899)

0.057

1.750 (0.976–4.523)

0.148

  1. HR hazard ratio, IMDC International Metastatic RCC Database Consortium, TF tumor fraction.
Back to article page